The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2015

Filed:

Mar. 15, 2013
Applicant:

Institute for Cancer Research, Philadelphia, PA (US);

Inventors:

Greg H. Enders, Villanova, PA (US);

Mark Andrake, Huntingdon Valley, PA (US);

Michael J. Hall, Glenside, PA (US);

Biao Luo, Princeton, NJ (US);

Timothy J. Yen, Haverford, PA (US);

Assignee:

Institute for Cancer Research, Philadelphia, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); C12Q 1/68 (2006.01); G01N 33/574 (2006.01); G06F 19/10 (2011.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G01N 33/57446 (2013.01); C12Q 2600/156 (2013.01); G06F 19/10 (2013.01);
Abstract

Systems and methods for diagnosing or characterizing a predisposition to colon cancer are provided. Cell nuclei may be evaluated for the presence or quantity of gamma-H2AX foci. Nucleic acids may be evaluated for the presence, type, or quantity of genomic instability or surrogates of dsDNA breaks such as ataxia telangiectasia mutated (ATM), Rad3-related protein (ATR), and Tumor suppressor p53-binding protein 1 (53BP1) in gamma-H2AX foci. Nucleic acids comprising a germline nucleic acid sequence of the ERCC6, WRN, TERT, and FAAP100 genes may be sequenced or probed to determine if the nucleic acid sequence includes one or more alterations that cause genomic instability, dsDNA breaks, or gamma-H2AX foci or otherwise predispose a subject to develop colon cancer.


Find Patent Forward Citations

Loading…